The first question almost every patient asks me about Transcranial Magnetic Stimulation isn't "Will it work for me?" It's "Is it safe?"That instinct is right. Anyone considering a brain-based treatment deserves a clear, honest answer — not marketing copy and not internet horror stories. The good news: TMS has one of the cleanest safety profiles of any treatment we use in psychiatry. The more useful answer goes a layer deeper than that, because safe doesn't mean zero risk, and patients deserve to understand what the actual risks are, how often they occur, and how clinical screening reduces them further.

The short version-TMS is non-invasive. There is no anesthesia, no sedation, no recovery time, and no implants. You walk into the clinic, you sit in a chair, you walk out and resume your day. Decades of clinical use and tens of thousands of published patient-sessions across multiple countries have produced a side-effect profile that, compared to most psychiatric medications and certainly compared to ECT, is unusually mild.The most common side effects — scalp discomfort and mild headache — are short-lived and typically resolve within the first week of treatment. The most serious theoretical risk — a seizure — occurs in roughly 1 in 35,000 sessions in published data, and proper screening before treatment reduces this further. Cognitive side effects, weight gain, sexual side effects, and sleep disturbance — all of which patients commonly experience on antidepressants — are not features of TMS treatment.That's the headline. 

The rest of this article unpacks each of these claims so you can evaluate them with the same scrutiny I'd want my own family member to apply.


How TMS works (briefly), and why that matters for safety

TMS uses a focused magnetic pulse, delivered through a coil held against the scalp, to stimulate a specific region of the brain — most commonly the left dorsolateral prefrontal cortex, an area implicated in mood regulation. The magnetic field passes harmlessly through the skull and induces a small electrical current in the targeted neurons.Three features of this mechanism are directly relevant to safety:

It is focal. The magnetic field decays sharply with distance, which means the stimulation is largely confined to a small region of cortex (a few centimeters across). It is not a whole-brain treatment.

It is non-invasive. Nothing crosses the skin. Nothing is implanted. There is no incision, no electrode placement, no anesthesia.

It is reversible. Each session is a discrete event. Once the coil is removed, no stimulation is being delivered. There is no medication metabolizing in your system afterward.

This is why most of the side effects are local (scalp, jaw, head) rather than systemic, and why TMS does not interact with most medications, food, or alcohol the way pharmaceutical antidepressants do.


What patients actually feel during a session

I find that hearing the unfiltered description of a session calms most safety concerns more than any statistic does.

You are seated in a reclining chair, fully awake. The technician positions the magnetic coil against the side of your head and runs a brief calibration ("motor threshold determination") on the first day to set your individual stimulation level. Then the actual treatment begins.

What you feel is a rapid tapping sensation on the scalp, in time with the magnetic pulses. Most patients describe it as unusual on the first day and unremarkable by the third or fourth. Some describe a contraction of the small muscles near the temple or jaw — a normal response to stimulation of nearby motor fibers. You can talk, listen to music, or watch something on your phone during the session.

A conventional rTMS session lasts approximately 19 minutes. Newer theta-burst protocols (iTBS) compress this into roughly 3 minutes. After the session ends, you stand up, leave, and drive yourself home or back to work.

That is the entirety of the experience. There is no anesthesia recovery, no observation period, no driving restriction.


Side effects: what's common, what's rare, what's serious

It helps to separate the conversation about side effects into three tiers.

Common, mild, short-lived

Scalp discomfort or pain at the stimulation site.

 Reported by roughly 25–40% of patients in the first week. The sensation is concentrated where the coil contacts the head and typically fades once the brain adapts. We can sometimes adjust coil angle or intensity to reduce it.

Mild headache.

 Roughly 20–30% of patients report a mild tension-type headache after early sessions. It usually responds to standard over-the-counter analgesics (paracetamol or ibuprofen) and resolves within the first week or two of treatment.

Facial muscle twitching during stimulation. 

Many patients notice a small contraction near the temple or eyebrow during the magnetic pulse. This is harmless — it reflects stimulation of nearby motor pathways — and stops the moment the pulse stops.These are the side effects ~80% of TMS-related conversations should be about, because they're what nearly every patient will actually experience.

Uncommon

Lightheadedness. 

A small percentage of patients feel briefly lightheaded after standing up post-session. Drinking water and resting briefly resolves it.

Hearing changes. 

The TMS coil produces a loud clicking sound during stimulation. We provide ear protection at every session, which prevents auditory issues. There are no documented cases of permanent hearing change in patients who consistently used the provided ear protection.

Rare but serious

Seizure. 

This is the side effect most people have heard about and want to understand.In published literature, the seizure rate during TMS is approximately 1 in 30,000 to 1 in 35,000 sessions with conventional protocols. To put that in everyday terms: a typical patient receiving 30 sessions over a treatment course has a per-course risk that is meaningfully lower than the general-population risk of having an unprovoked seizure during the same time window.

The rate is reduced further by clinical screening. Standard pre-treatment screening identifies patients who are at higher seizure risk — for example, those with a history of seizures, those on medications that lower the seizure threshold, those with significant alcohol or sedative withdrawal, or those with certain neurological conditions — and either modifies the protocol or recommends a different treatment.

When a seizure does occur during TMS, it is almost always isolated, self-limited, and resolves with no lasting effects. It is not the same clinical situation as epilepsy.

This is the right way to weigh the seizure question: it is a real but uncommon event, the risk is largely predictable in advance, and the screening process is designed to identify the patients in whom the risk is non-negligible.


What TMS does not cause

This list matters as much as the side-effect list, because it explains why so many patients with treatment-resistant depression find TMS easier to tolerate than yet another medication trial.

No memory loss. 

TMS does not cause the cognitive or memory side effects associated with ECT. Multiple long-term cognitive studies of patients who have undergone TMS show no decline — and in patients whose depression responds, cognitive function often improves as the depression itself lifts.

No weight gain. 

Weight gain is one of the most common reasons patients discontinue antidepressants. TMS does not cause weight gain.

No sexual side effects. 

SSRIs and SNRIs frequently cause reduced libido, delayed orgasm, or other sexual dysfunction — for many patients, this is the deal-breaker. TMS does not cause these effects.No emotional blunting. Some patients on long-term antidepressants describe feeling emotionally flat — better than the depression but not fully alive. TMS does not produce this.

No sleep disturbance.

 No insomnia, no abnormal dreaming, no morning sedation.No anesthesia, no fasting, no recovery period. You eat normally before and after.

No interaction with most medications, alcohol, or food. 

Patients can continue their existing medication regimens, including antidepressants, mood stabilizers, and most other psychiatric or general medical drugs.This is the comparison that most often surprises patients: the same person who has spent years adjusting medications to manage side effects often finds TMS sessions essentially side-effect-free by the second week.

Who should not get TMS

Honest safety information includes the patients for whom TMS is not appropriate. The standard contraindications are:

Metallic implants in or near the head.

Cochlear implants, deep brain stimulators, vagal nerve stimulators, aneurysm clips, certain dental implants, and metallic fragments in the head can interact with the magnetic field. Standard dental fillings and braces are generally fine. Each case is reviewed individually before treatment.

Active seizure disorder, or significantly elevated seizure risk.

 Patients with epilepsy or active risk factors for seizure are typically not candidates for standard TMS protocols. In some cases, modified protocols are possible after specialist consultation.

Pregnancy. 

TMS in pregnancy is an area of active research with growing evidence of safety, but routine clinical practice is conservative — a careful risk-benefit conversation with the patient and obstetrician is required before any treatment decision.

Acute psychiatric instability. 

TMS is generally not used as a first-line treatment in acute crisis (active suicidality requiring inpatient care, acute psychosis). Stabilization comes first; TMS may be appropriate afterward.

A proper clinical evaluation before TMS goes through this checklist methodically. If a clinic is not screening you for these factors, that itself is a safety signal worth attending to.


How TMS compares to other treatment options

Patients sometimes ask, "Compared to what?" — which is the right question, because no medical decision exists in isolation.

Compared to a fourth or fifth antidepressant trial: 

TMS has a more favorable side-effect profile (no weight gain, no sexual side effects, no emotional blunting) and a higher published response rate in treatment-resistant patients. Antidepressants have the advantages of being inexpensive and home-based; TMS has the advantage of being targeted, time-limited, and free of the systemic side effects that drive medication discontinuation.

Compared to ECT: 

ECT is more powerful and is still the right answer in some clinical situations — particularly severe depression with active suicidality, catatonia, or psychotic features. TMS is gentler: it requires no anesthesia, causes no memory side effects, and allows the patient to drive home immediately after each session. In modern practice, TMS is typically tried before ECT in most patients who are not in acute crisis.

Compared to ketamine therapy: 

These are different tools. Ketamine acts faster (sometimes within hours) but is delivered under medical supervision with a different side-effect profile. TMS works more gradually but has a near-complete absence of medication-like side effects. Some patients are good candidates for one and not the other; some benefit from a sequence.The point isn't that TMS is universally superior — no treatment is. 

The point is that on the specific question of safety, TMS sits at the favourable end of the spectrum among effective treatments for depression and OCD.

What good clinical practice looks like

Safety in TMS is partly about the technology and partly about the clinic. 

The questions worth asking before starting treatment:

Is there a structured pre-treatment evaluation that screens for seizure risk, metallic implants, medication interactions, and pregnancy status?

Is your motor threshold being individually calibrated at the start of treatment, rather than a fixed setting being applied to every patient?

Is the coil position being marked or measured so that the same brain target is stimulated at each session?

Is a physician available to discuss any side effects you experience, and to adjust protocol parameters if needed?

Is the protocol being matched to your diagnosis (rTMS vs. theta burst vs. accelerated, left vs. right cortex), rather than a single "house protocol" applied to everyone?

A good clinic will answer these questions clearly and unhurriedly.


The bottom line

TMS is among the safest active treatments we have for depression, OCD, and several other conditions in psychiatry. The common side effects are mild and short-lived. The serious risks are rare and largely predictable in advance. The treatment does not cause the cognitive, weight, sexual, or sleep side effects that drive so many patients away from antidepressants.

Safety, properly understood, is not just "can this hurt me?" — it is "compared to my other options, what is the best risk-benefit fit for my situation?" For a substantial group of patients, particularly those who have not responded fully to medications or who have struggled with side effects, TMS sits favorably on that comparison.

If you are considering TMS — for yourself or someone close to you — the right next step is a thorough clinical evaluation. A proper evaluation tells you whether TMS is the right protocol, what to expect, and what the realistic outcomes are based on your diagnosis and history. That conversation is more useful than any general article, including this one.